Clinical Usefulness of Serum Lactate Dehydrogenase Levels in Mycoplasma pneumoniae Pneumonia in Children.
Children
Lactate dehydrogenase
Mycoplasma pneumonia
Pneumonia
Prediction
Refractory
Journal
Indian journal of pediatrics
ISSN: 0973-7693
Titre abrégé: Indian J Pediatr
Pays: India
ID NLM: 0417442
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
08
10
2021
accepted:
16
02
2022
pubmed:
7
6
2022
medline:
21
9
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
To elucidate the clinical usefulness of lactate dehydrogenase (LDH) levels in children with Mycoplasma pneumoniae (MP) pneumonia and identify cut-off levels in various clinical conditions. The study was retrospectively performed in 145 children who were hospitalized with MP pneumonia. Laboratory findings, including LDH levels at admission and clinical features were retrospectively reviewed from patients' electronic medical records. The mean age of the study population was 5.9 y, and the mean value of LDH was 809.7 U/L. Poor response to treatment for MP pneumonia, respiratory virus coinfection, severe MP pneumonia, development of postinfectious bronchiolitis obliterans (PIBO) after MP pneumonia, pleural effusion, and oxygen need during illness were significantly associated with serum LDH levels. The cutoff levels of LDH for predicting poor response to treatment for MP pneumonia and respiratory virus coinfection were 1058 U/L [area under the curve (AUC), 0.729] and 803 U/L (AUC, 0.682), respectively. Those for pneumonic lesions involving at least one-third of the total lung volume, prediction of PIBO development, and extrapulmonary manifestations were 1098 U/L (AUC, 0.715), 676 U/L (AUC, 0.714), and 859 U/L (AUC, 0.710), respectively. The cutoff levels for pleural effusion during illness and for the prediction of oxygen need were 894 U/L (AUC, 0.699) and 1114 U/L (AUC, 0.771), respectively. LDH levels are elevated in diverse clinical conditions in children with MP pneumonia and may be useful in the identification of severe clinical courses of MP pneumonia in children.
Identifiants
pubmed: 35665905
doi: 10.1007/s12098-022-04205-0
pii: 10.1007/s12098-022-04205-0
doi:
Substances chimiques
L-Lactate Dehydrogenase
EC 1.1.1.27
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1009Informations de copyright
© 2022. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.
Références
Lee E, Kim CH, Lee YJ, et al. Annual and seasonal patterns in etiologies of pediatric community-acquired pneumonia due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization in South Korea. BMC Infect Dis. 2020;20:132.
doi: 10.1186/s12879-020-4810-9
Søndergaard MJ, Friis MB, Hansen DS, Jørgensen IM. Clinical manifestations in infants and children with Mycoplasma pneumoniae infection. PloS One. 2018;13:e0195288.
Lee E, Cho HJ, Hong SJ, Lee J, Sung H, Yu J. Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children. Korean J Pediatr. 2017;60:151–7.
doi: 10.3345/kjp.2017.60.5.151
Lee E, Young Lee Y. Risk factors for the development of post-infectious bronchiolitis obliterans after Mycoplasma pneumoniae pneumonia in the era of increasing macrolide resistance. Respir Med. 2020;175:106209.
Kim YS, Lee YY, Lee E. Cases of macrolide-resistant Mycoplasma pneumoniae pneumonia-associated pulmonary thromboembolism. Pediatr Pulmonol. 2021;56:1796–9.
doi: 10.1002/ppul.25298
Lee H, Yun KW, Lee HJ, Choi EH. Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Expert Rev Anti Infect Ther. 2018;16:23–34.
doi: 10.1080/14787210.2018.1414599
Narita M. Classification of extrapulmonary manifestations due to mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol. 2016;7:23.
doi: 10.3389/fmicb.2016.00023
Poddighe D. Extra-pulmonary diseases related to Mycoplasma pneumoniae in children: recent insights into the pathogenesis. Curr Opin Rheumatol. 2018;30:380–7.
doi: 10.1097/BOR.0000000000000494
Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z. The clinical characteristics and predictors of refractory mycoplasma pneumoniae pneumonia in children. Plos One. 2016;11:e0156465.
Gong H, Sun B, Chen Y, Chen H. The risk factors of children acquiring refractory mycoplasma pneumoniae pneumonia: A meta-analysis. Medicine (Baltimore). 2021;100:e24894.
Cheng S, Lin J, Zheng X, et al. Development and validation of a simple-to-use nomogram for predicting refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2020;55:968–74.
doi: 10.1002/ppul.24684
Wu MY, Yao L, Wang Y, et al. Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respir Res. 2020;21:171.
doi: 10.1186/s12931-020-01427-8
Yan Y, Wei Y, Jiang W, Hao C. The clinical characteristics of corticosteroid-resistant refractory Mycoplasma Pneumoniae pneumonia in children. Sci Rep. 2016;6:39929.
doi: 10.1038/srep39929
Inamura N, Miyashita N, Hasegawa S, et al. Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother. 2014;20:270–3.
doi: 10.1016/j.jiac.2014.01.001
Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate dehydrogenase as a biomarker for prediction of refractory mycoplasma pneumoniae pneumonia in children. Respir Care. 2015;60:1469–75.
doi: 10.4187/respcare.03920
Lee E, Lee YY. Predictive factors of the responses to treatment of mycoplasma pneumoniae pneumonia. J Clin Med. 2021;10:1154.
doi: 10.3390/jcm10061154
Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol. 2016;7:974.
doi: 10.3389/fmicb.2016.00974
Sun LL, Ye C, Zhou YL, Zuo SR, Deng ZZ, Wang CJ. Meta-analysis of the clinical efficacy and safety of high- and low-dose methylprednisolone in the treatment of children with severe mycoplasma pneumoniae pneumonia. Pediatr Infect Dis J. 2020;39:177–83.
doi: 10.1097/INF.0000000000002529
Kim HS, Sol IS, Li D, et al. Efficacy of glucocorticoids for the treatment of macrolide refractory mycoplasma pneumonia in children: meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19:251.
doi: 10.1186/s12890-019-0990-8
Yang EA, Kang HM, Rhim JW, Kang JH, Lee KY. Early corticosteroid therapy for mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. J Clin Med. 2019;8:726.
doi: 10.3390/jcm8050726
Qiu JL, Huang L, Shao MY, et al. Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2020;99:e20121.
Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2021;54:557–65.
doi: 10.1016/j.jmii.2020.10.002
Ishiguro N, Koseki N, Kaiho M, et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PloS one. 2017;12:e0173635.
Chen IC, Hsu JS, Chen YW, et al. Post-infectious bronchiolitis obliterans: HRCT, DECT, Pulmonary Scintigraphy images, and clinical follow-up in eight children. Front Pediatr. 2020;8:622065.
Kim KW, Sung JJ, Tchah H, et al. Hepatitis associated with Mycoplasma pneumoniae infection in Korean children: a prospective study. Korean J Pediatr. 2015;58:211–7.
doi: 10.3345/kjp.2015.58.6.211
Oishi T, Narita M, Matsui K, et al. Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia. J Infect Chemother. 2011;17:803–6.
doi: 10.1007/s10156-011-0265-7
Huang L, Huang X, Jiang W, Zhang R, Yan Y, Huang L. Independent predictors for longer radiographic resolution in patients with refractory mycoplasma pneumoniae pneumonia: a prospective cohort study. BMJ Open. 2018;8:e023719.
Lee KL, Lee CM, Yang TL, et al. Severe mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010–2019. J Formos Med Assoc. 2021;120:281–91.
doi: 10.1016/j.jfma.2020.08.018
Safari S, Baratloo A, Elfil M, Negida A. Evidence based emergency medicine; part 5 receiver operating curve and area under the curve. emerg (Tehran). 2016;4:111–3.